{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T13:45:39Z","timestamp":1781531139994,"version":"3.54.5"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T00:00:00Z","timestamp":1623196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T00:00:00Z","timestamp":1623196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose of Review<\/jats:title><jats:p>Amyloidosis is a protein deposition disease whereby a variety of precursor proteins form insoluble fibrils that deposit in tissues, causing organ dysfunction and, many times, death. Accurate characterization of the disease based on the nature of the precursor protein, organ involvement, and extent of disease is paramount to guide management. Cardiac amyloidosis is critical to understand because of its impact on prognosis and new treatment options available.<\/jats:p><\/jats:sec><jats:sec><jats:title>Recent Findings<\/jats:title><jats:p>New imaging methods have proven to be considerably valuable in the identification of cardiac amyloid infiltration. For treating clinicians, a diagnostic algorithm for patients with suspected amyloidosis with or without cardiomyopathy is shown to help classify disease and to direct appropriate genetic testing and management. For patients with light chain disease, recently introduced treatments adopted from multiple myeloma therapies have significantly extended progression-free and overall survival as well as organ response. In addition, new medical interventions are now available for those with transthyretin amyloidosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Summary<\/jats:title><jats:p>Although cardiac amyloidosis contributes significantly to the morbidity and mortality associated with systemic disease, new tools are available to assist with diagnosis, prognosis, and management.<\/jats:p><\/jats:sec>","DOI":"10.1007\/s11899-021-00626-4","type":"journal-article","created":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T10:04:01Z","timestamp":1623233041000},"page":"357-366","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Amyloidosis with Cardiac Involvement: Identification, Characterization, and Management"],"prefix":"10.1007","volume":"16","author":[{"given":"Faizi","family":"Jamal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5158-5131","authenticated-orcid":false,"given":"Michael","family":"Rosenzweig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,9]]},"reference":[{"issue":"13","key":"626_CR1","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1056\/NEJM199709253371306","volume":"337","author":"RH Falk","year":"1997","unstructured":"Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med. 1997;337(13):898\u2013909.","journal-title":"N Engl J Med"},{"issue":"4","key":"626_CR2","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.3181\/00379727-131-34110","volume":"131","author":"L Bonar","year":"1969","unstructured":"Bonar L, Cohen AS, Skinner MM. Characterization of the amyloid fibril as a cross-beta protein. Proc Soc Exp Biol Med. 1969;131(4):1373\u20135.","journal-title":"Proc Soc Exp Biol Med"},{"key":"626_CR3","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1146\/annurev.me.25.020174.001023","volume":"25","author":"GG Glenner","year":"1974","unstructured":"Glenner GG, Terry WD. Characterization of amyloid. Annu Rev Med. 1974;25:131\u20135.","journal-title":"Annu Rev Med"},{"issue":"12","key":"626_CR4","doi-asserted-by":"publisher","first-page":"5602","DOI":"10.1073\/pnas.91.12.5602","volume":"91","author":"MB Pepys","year":"1994","unstructured":"Pepys MB, Rademacher TW, Amatayakul-Chantler S, Williams P, Noble GE, Hutchinson WL, et al. Human serum amyloid P component is an invariant constituent of amyloid deposits and has a uniquely homogeneous glycostructure. Proc Natl Acad Sci U S A. 1994;91(12):5602\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"626_CR5","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/j.1365-2559.1994.tb00001.x","volume":"25","author":"SY Tan","year":"1994","unstructured":"Tan SY, Pepys MB. Amyloidosis. Histopathology. 1994;25(5):403\u201314.","journal-title":"Histopathology"},{"issue":"10038","key":"626_CR6","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1016\/S0140-6736(15)01274-X","volume":"387","author":"AD Wechalekar","year":"2016","unstructured":"Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet. 2016;387(10038):2641\u201354.","journal-title":"Lancet"},{"issue":"1","key":"626_CR7","doi-asserted-by":"publisher","first-page":"141","DOI":"10.3324\/haematol.2012.068155","volume":"98","author":"AJ Cowan","year":"2013","unstructured":"Cowan AJ, Skinner M, Seldin DC, Berk JL, Lichtenstein DR, O'Hara CJ, et al. Amyloidosis of the gastrointestinal tract: a 13-year, single-center, referral experience. Haematologica. 2013;98(1):141\u20136.","journal-title":"Haematologica"},{"issue":"4","key":"626_CR8","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/ajh.20381","volume":"79","author":"MA Gertz","year":"2005","unstructured":"Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol. 2005;79(4):319\u201328.","journal-title":"Am J Hematol"},{"key":"626_CR9","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1002\/ajh.25915","volume":"95","author":"M Basset","year":"2020","unstructured":"Basset M, Hummedah K, Kimmich C, Veelken K, Dittrich T, Brandelik S, et al. Localized immunoglobulin light chain amyloidosis: novel insights including prognostic factors for local progression. Am J Hematol. 2020;95:1158\u201369.","journal-title":"Am J Hematol"},{"issue":"4","key":"626_CR10","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3109\/13506129.2014.964858","volume":"21","author":"JD Sipe","year":"2014","unstructured":"Sipe JD, Benson MD, Buxbaum JN, Ikeda SI, Merlini G, Saraiva MJM, et al. Nomenclature 2014: amyloid fibril proteins and clinical classification of the amyloidosis. Amyloid. 2014;21(4):221\u20134.","journal-title":"Amyloid"},{"issue":"13","key":"626_CR11","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1161\/CIRCULATIONAHA.104.489187","volume":"112","author":"RH Falk","year":"2005","unstructured":"Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation. 2005;112(13):2047\u201360.","journal-title":"Circulation"},{"issue":"10","key":"626_CR12","doi-asserted-by":"publisher","first-page":"3854","DOI":"10.1182\/blood-2005-11-4385","volume":"107","author":"G Palladini","year":"2006","unstructured":"Palladini G, Lavatelli F, Russo P, Perlini S, Perfetti V, Bosoni T, et al. Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood. 2006;107(10):3854\u20138.","journal-title":"Blood"},{"issue":"23","key":"626_CR13","doi-asserted-by":"publisher","first-page":"3543","DOI":"10.1182\/blood-2013-10-525634","volume":"123","author":"L Diomede","year":"2014","unstructured":"Diomede L, Rognoni P, Lavatelli F, Romeo M, del Favero E, Cant\u00f9 L, et al. A Caenorhabditis elegans-based assay recognizes immunoglobulin light chains causing heart amyloidosis. Blood. 2014;123(23):3543\u201352.","journal-title":"Blood"},{"issue":"17","key":"626_CR14","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1016\/j.jacc.2018.07.092","volume":"72","author":"BW Sperry","year":"2018","unstructured":"Sperry BW, Reyes BA, Ikram A, Donnelly JP, Phelan D, Jaber WA, et al. Tenosynovial and cardiac amyloidosis in patients undergoing carpal tunnel release. J Am Coll Cardiol. 2018;72(17):2040\u201350.","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"626_CR15","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","volume":"73","author":"FL Ruberg","year":"2019","unstructured":"Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin amyloid cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019;73(22):2872\u201391.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"626_CR16","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.rdc.2018.06.004","volume":"44","author":"R Papa","year":"2018","unstructured":"Papa R, Lachmann HJ. Secondary, AA, Amyloidosis. Rheum Dis Clin N Am. 2018;44(4):585\u2013603.","journal-title":"Rheum Dis Clin N Am"},{"issue":"7","key":"626_CR17","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41582-019-0210-4","volume":"15","author":"D Adams","year":"2019","unstructured":"Adams D, Koike H, Slama M, Coelho T. Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease. Nat Rev Neurol. 2019;15(7):387\u2013404.","journal-title":"Nat Rev Neurol"},{"key":"626_CR18","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1750-1172-8-31","volume":"8","author":"Y Ando","year":"2013","unstructured":"Ando Y, Coelho T, Berk JL, Cruz MW, Ericzon BG, Ikeda SI, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis. 2013;8:31.","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"626_CR19","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","volume":"68","author":"MS Maurer","year":"2016","unstructured":"Maurer MS, Hanna M, Grogan M, Dispenzieri A, Witteles R, Drachman B, et al. Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol. 2016;68(2):161\u201372.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"626_CR20","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.jchf.2020.04.007","volume":"8","author":"VS Hahn","year":"2020","unstructured":"Hahn VS, Yanek LR, Vaishnav J, Ying W, Vaidya D, Lee YZJ, et al. Endomyocardial biopsy characterization of heart failure with preserved ejection fraction and prevalence of cardiac amyloidosis. JACC Heart Fail. 2020;8(9):712\u201324.","journal-title":"JACC Heart Fail"},{"issue":"9","key":"626_CR21","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","volume":"30","author":"S Kumar","year":"2012","unstructured":"Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012;30(9):989\u201395.","journal-title":"J Clin Oncol"},{"issue":"10","key":"626_CR22","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1038\/leu.2016.191","volume":"30","author":"G Merlini","year":"2016","unstructured":"Merlini G, Lousada I, Ando Y, Dispenzieri A, Gertz MA, Grogan M, et al. Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis. Leukemia. 2016;30(10):1979\u201386.","journal-title":"Leukemia"},{"issue":"19","key":"626_CR23","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1136\/heartjnl-2012-302353","volume":"98","author":"D Phelan","year":"2012","unstructured":"Phelan D, Collier P, Thavendiranathan P, Popovi\u0107 ZB, Hanna M, Plana JC, et al. Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart. 2012;98(19):1442\u20138.","journal-title":"Heart"},{"key":"626_CR24","doi-asserted-by":"crossref","unstructured":"\u2022 Dorbala S, et al. ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2-evidence base and standardized methods of imaging. J Nucl Cardiol. 2019;26(6):2065\u2013123. This text provides guidelines for imaging in patients with suspected cardiac amyloidosis.","DOI":"10.1007\/s12350-019-01760-6"},{"key":"626_CR25","doi-asserted-by":"crossref","unstructured":"\u2022 Rapezzi C, et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation. 2009;120(13):1203\u201312. Nuances in the various subtypes of cardiac amyloidosis are highlighted.","DOI":"10.1161\/CIRCULATIONAHA.108.843334"},{"issue":"4","key":"626_CR26","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.jacc.2017.05.053","volume":"70","author":"A Martinez-Naharro","year":"2017","unstructured":"Martinez-Naharro A, Treibel TA, Abdel-Gadir A, Bulluck H, Zumbo G, Knight DS, et al. Magnetic resonance in transthyretin cardiac amyloidosis. J Am Coll Cardiol. 2017;70(4):466\u201377.","journal-title":"J Am Coll Cardiol"},{"issue":"14","key":"626_CR27","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1161\/CIRCULATIONAHA.116.024438","volume":"135","author":"MS Maurer","year":"2017","unstructured":"Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis. Circulation. 2017;135(14):1357\u201377.","journal-title":"Circulation"},{"issue":"2","key":"626_CR28","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1161\/01.CIR.0000152819.97857.9D","volume":"111","author":"AM Maceira","year":"2005","unstructured":"Maceira AM, Joshi J, Prasad SK, Moon JC, Perugini E, Harding I, et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2005;111(2):186\u201393.","journal-title":"Circulation"},{"issue":"5","key":"626_CR29","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1002\/ehf2.12511","volume":"6","author":"J Brownrigg","year":"2019","unstructured":"Brownrigg J, Lorenzini M, Lumley M, Elliott P. Diagnostic performance of imaging investigations in detecting and differentiating cardiac amyloidosis: a systematic review and meta-analysis. ESC Heart Fail. 2019;6(5):1041\u201351.","journal-title":"ESC Heart Fail"},{"issue":"16","key":"626_CR30","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1161\/CIRCULATIONAHA.115.016567","volume":"132","author":"M Fontana","year":"2015","unstructured":"Fontana M, Pica S, Reant P, Abdel-Gadir A, Treibel TA, Banypersad SM, et al. Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2015;132(16):1570\u20139.","journal-title":"Circulation"},{"issue":"11","key":"626_CR31","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/j.jcmg.2016.01.036","volume":"9","author":"S Raina","year":"2016","unstructured":"Raina S, Lensing SY, Nairooz RS, Pothineni NV, Hakeem A, Bhatti S, et al. Prognostic value of late gadolinium enhancement CMR in systemic amyloidosis. JACC Cardiovasc Imaging. 2016;9(11):1267\u201377.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"1","key":"626_CR32","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.jcmg.2017.02.012","volume":"11","author":"A Martinez-Naharro","year":"2018","unstructured":"Martinez-Naharro A, Abdel-Gadir A, Treibel TA, Zumbo G, Knight DS, Rosmini S, et al. CMR-verified regression of cardiac AL amyloid after chemotherapy. JACC Cardiovasc Imaging. 2018;11(1):152\u20134.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"8","key":"626_CR33","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1001\/jamacardio.2016.2839","volume":"1","author":"A Castano","year":"2016","unstructured":"Castano A, Haq M, Narotsky DL, Goldsmith J, Weinberg RL, Morgenstern R, et al. Multicenter study of planar technetium 99m pyrophosphate cardiac imaging: predicting survival for patients with ATTR cardiac amyloidosis. JAMA Cardiol. 2016;1(8):880\u20139.","journal-title":"JAMA Cardiol"},{"issue":"4","key":"626_CR34","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/joim.12585","volume":"281","author":"OB Suhr","year":"2017","unstructured":"Suhr OB, Lundgren E, Westermark P. One mutation, two distinct disease variants: unravelling the impact of transthyretin amyloid fibril composition. J Intern Med. 2017;281(4):337\u201347.","journal-title":"J Intern Med"},{"key":"626_CR35","unstructured":"\u2022 Gillmore JD, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133(24):2404\u201312. This article illustrates the ability to identify cardiac transthyretin amyloidosis without biopsy."},{"issue":"9","key":"626_CR36","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1007\/s00259-014-2787-6","volume":"41","author":"S Dorbala","year":"2014","unstructured":"Dorbala S, Vangala D, Semer J, Strader C, Bruyere JR Jr, di Carli MF, et al. Imaging cardiac amyloidosis: a pilot study using (1)(8)F-florbetapir positron emission tomography. Eur J Nucl Med Mol Imaging. 2014;41(9):1652\u201362.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"626_CR37","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.2967\/jnumed.115.169870","volume":"57","author":"WP Law","year":"2016","unstructured":"Law WP, Wang WYS, Moore PT, Mollee PN, Ng ACT. Cardiac amyloid imaging with 18F-florbetaben PET: a pilot study. J Nucl Med. 2016;57(11):1733\u20139.","journal-title":"J Nucl Med"},{"issue":"4","key":"626_CR38","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1007\/s002590050406","volume":"26","author":"N Delahaye","year":"1999","unstructured":"Delahaye N, Dinanian S, Slama MS, Mzabi H, Samuel D, Adams D, et al. Cardiac sympathetic denervation in familial amyloid polyneuropathy assessed by iodine-123 metaiodobenzylguanidine scintigraphy and heart rate variability. Eur J Nucl Med. 1999;26(4):416\u201324.","journal-title":"Eur J Nucl Med"},{"issue":"7","key":"626_CR39","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1007\/s00259-018-3963-x","volume":"45","author":"E Piekarski","year":"2018","unstructured":"Piekarski E, Chequer R, Algalarrondo V, Eliahou L, Mahida B, Vigne J, et al. Cardiac denervation evidenced by MIBG occurs earlier than amyloid deposits detection by diphosphonate scintigraphy in TTR mutation carriers. Eur J Nucl Med Mol Imaging. 2018;45(7):1108\u201318.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"626_CR40","doi-asserted-by":"publisher","first-page":"E2403","DOI":"10.1002\/humu.22619","volume":"35","author":"DM Rowczenio","year":"2014","unstructured":"Rowczenio DM, Noor I, Gillmore JD, Lachmann HJ, Whelan C, Hawkins PN, et al. Online registry for mutations in hereditary amyloidosis including nomenclature recommendations. Hum Mutat. 2014;35(9):E2403\u201312.","journal-title":"Hum Mutat"},{"issue":"4","key":"626_CR41","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1093\/clinchem\/47.4.673","volume":"47","author":"AR Bradwell","year":"2001","unstructured":"Bradwell AR, Carr-Smith HD, Mead GP, Tang LX, Showell PJ, Drayson MT, et al. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem. 2001;47(4):673\u201380.","journal-title":"Clin Chem"},{"issue":"6","key":"626_CR42","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1002\/art.21902","volume":"54","author":"II Van Gameren","year":"2006","unstructured":"Van Gameren II, et al. Diagnostic accuracy of subcutaneous abdominal fat tissue aspiration for detecting systemic amyloidosis and its utility in clinical practice. Arthritis Rheum. 2006;54(6):2015\u201321.","journal-title":"Arthritis Rheum"},{"issue":"24","key":"626_CR43","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1093\/eurheartj\/ehx047","volume":"38","author":"CC Quarta","year":"2017","unstructured":"Quarta CC, Gonzalez-Lopez E, Gilbertson JA, Botcher N, Rowczenio D, Petrie A, et al. Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis. Eur Heart J. 2017;38(24):1905\u20138.","journal-title":"Eur Heart J"},{"issue":"1","key":"626_CR44","doi-asserted-by":"publisher","first-page":"14","DOI":"10.5858\/2008-132-14a-UOIFTA","volume":"132","author":"A Solomon","year":"2008","unstructured":"Solomon A, Murphy CL, Westermark P. Unreliability of immunohistochemistry for typing amyloid deposits. Arch Pathol Lab Med. 2008;132(1):14 author reply 14-5.","journal-title":"Arch Pathol Lab Med"},{"key":"626_CR45","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1146\/annurev-pathol-052016-100200","volume":"12","author":"A Dogan","year":"2017","unstructured":"Dogan A. Amyloidosis: insights from proteomics. Annu Rev Pathol. 2017;12:277\u2013304.","journal-title":"Annu Rev Pathol"},{"issue":"23","key":"626_CR46","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1182\/blood.2020006913","volume":"136","author":"G Palladini","year":"2020","unstructured":"Palladini G, Milani P, Merlini G. Management of AL amyloidosis in 2020. Blood. 2020;136(23):2620\u20137.","journal-title":"Blood"},{"key":"626_CR47","doi-asserted-by":"crossref","unstructured":"\u2022 Palladini G, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012;30(36):4541\u20139. This manuscript demonstrates the importance of biomarkers and their utility in patient management.","DOI":"10.1200\/JCO.2011.37.7614"},{"issue":"11","key":"626_CR48","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1002\/ajh.25940","volume":"95","author":"E Muchtar","year":"2020","unstructured":"Muchtar E, Gertz MA, Lacy MQ, Leung N, Buadi FK, Dingli D, et al. Refining amyloid complete hematological response: quantitative serum free light chains superior to ratio. Am J Hematol. 2020;95(11):1280\u20137.","journal-title":"Am J Hematol"},{"issue":"15","key":"626_CR49","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1182\/blood-2014-04-570010","volume":"124","author":"G Palladini","year":"2014","unstructured":"Palladini G, Hegenbart U, Milani P, Kimmich C, Foli A, Ho AD, et al. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood. 2014;124(15):2325\u201332.","journal-title":"Blood"},{"issue":"4","key":"626_CR50","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41408-020-0306-5","volume":"10","author":"S Sidana","year":"2020","unstructured":"Sidana S, Milani P, Binder M, Basset M, Tandon N, Foli A, et al. A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis. Blood Cancer J. 2020;10(4):41.","journal-title":"Blood Cancer J"},{"issue":"3","key":"626_CR51","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1111\/bjh.16198","volume":"188","author":"B Lilleness","year":"2020","unstructured":"Lilleness B, Doros G, Ruberg FL, Sanchorawala V. Establishment of brain natriuretic peptide - based criteria for evaluating cardiac response to treatment in light chain (AL) amyloidosis. Br J Haematol. 2020;188(3):424\u20137.","journal-title":"Br J Haematol"},{"issue":"4","key":"626_CR52","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/s41409-018-0284-4","volume":"54","author":"C Varga","year":"2019","unstructured":"Varga C, Comenzo RL. High-dose melphalan and stem cell transplantation in systemic AL amyloidosis in the era of novel anti-plasma cell therapy: a comprehensive review. Bone Marrow Transplant. 2019;54(4):508\u201318.","journal-title":"Bone Marrow Transplant"},{"key":"626_CR53","doi-asserted-by":"crossref","unstructured":"Cornell RF, et al. Bortezomib induction prior to autologous hematopoietic cell transplantation (AHCT) for newly diagnosed light chain amyloidosis (AL): A study of 426 patients. J Clin Oncol. 2020;38(15_suppl):8515\u20138515.","DOI":"10.1200\/JCO.2020.38.15_suppl.8515"},{"issue":"20","key":"626_CR54","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1182\/blood-2015-08-662726","volume":"126","author":"V Sanchorawala","year":"2015","unstructured":"Sanchorawala V, Sun F, Quillen K, Sloan JM, Berk JL, Seldin DC. Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience. Blood. 2015;126(20):2345\u20137.","journal-title":"Blood"},{"issue":"8","key":"626_CR55","doi-asserted-by":"publisher","first-page":"2936","DOI":"10.1182\/blood-2003-08-2788","volume":"103","author":"G Palladini","year":"2004","unstructured":"Palladini G, Perfetti V, Obici L, Caccialanza R, Semino A, Adami F, et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood. 2004;103(8):2936\u20138.","journal-title":"Blood"},{"issue":"10","key":"626_CR56","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.3324\/haematol.11325","volume":"92","author":"E Kastritis","year":"2007","unstructured":"Kastritis E, Anagnostopoulos A, Roussou M, Toumanidis S, Pamboukas C, Migkou M, et al. Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone. Haematologica. 2007;92(10):1351\u20138.","journal-title":"Haematologica"},{"issue":"7","key":"626_CR57","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1002\/ajh.25819","volume":"95","author":"MA Gertz","year":"2020","unstructured":"Gertz MA. Immunoglobulin light chain amyloidosis: 2020 update on diagnosis, prognosis, and treatment. Am J Hematol. 2020;95(7):848\u201360.","journal-title":"Am J Hematol"},{"issue":"28","key":"626_CR58","doi-asserted-by":"publisher","first-page":"3252","DOI":"10.1200\/JCO.20.01285","volume":"38","author":"E Kastritis","year":"2020","unstructured":"Kastritis E, Leleu X, Arnulf B, Zamagni E, Cibeira MT, Kwok F, et al. Bortezomib, melphalan, and dexamethasone for light-chain amyloidosis. J Clin Oncol. 2020;38(28):3252\u201360.","journal-title":"J Clin Oncol"},{"issue":"19","key":"626_CR59","doi-asserted-by":"publisher","first-page":"4387","DOI":"10.1182\/blood-2011-10-388462","volume":"119","author":"CP Venner","year":"2012","unstructured":"Venner CP, Lane T, Foard D, Rannigan L, Gibbs SDJ, Pinney JH, et al. Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood. 2012;119(19):4387\u201390.","journal-title":"Blood"},{"issue":"19","key":"626_CR60","doi-asserted-by":"publisher","first-page":"4391","DOI":"10.1182\/blood-2011-11-390930","volume":"119","author":"JR Mikhael","year":"2012","unstructured":"Mikhael JR, Schuster SR, Jimenez-Zepeda VH, Bello N, Spong J, Reeder CB, et al. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood. 2012;119(19):4391\u20134.","journal-title":"Blood"},{"issue":"1","key":"626_CR61","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1182\/blood.2019004460","volume":"136","author":"G Palladini","year":"2020","unstructured":"Palladini G, Kastritis E, Maurer MS, Zonder J, Minnema MC, Wechalekar AD, et al. Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. Blood. 2020;136(1):71\u201380.","journal-title":"Blood"},{"key":"626_CR62","doi-asserted-by":"crossref","unstructured":"Kastritis, E., et al., Subcutaneous daratumumab + cyclophosphamide, bortezomib, and dexamethasone (CYBORD) in patients with newly diagnosed light chain (AL) amyloidosis: primary results from the phase 3 ANDROMEDA. EHA25 Virtual, Abstract LB2604, 2020.","DOI":"10.1200\/JCO.2021.39.15_suppl.8003"},{"issue":"23","key":"626_CR63","doi-asserted-by":"publisher","first-page":"5397","DOI":"10.1182\/blood-2012-02-413161","volume":"119","author":"A Dispenzieri","year":"2012","unstructured":"Dispenzieri A, Buadi F, Laumann K, LaPlant B, Hayman SR, Kumar SK, et al. Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis. Blood. 2012;119(23):5397\u2013404.","journal-title":"Blood"},{"issue":"2","key":"626_CR64","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1182\/blood-2006-07-030544","volume":"109","author":"V Sanchorawala","year":"2007","unstructured":"Sanchorawala V, Wright DG, Rosenzweig M, Finn KT, Fennessey S, Zeldis JB, et al. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood. 2007;109(2):492\u20136.","journal-title":"Blood"},{"key":"626_CR65","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1182\/blood-2019-124409","volume":"134","author":"A Dispenzieri","year":"2019","unstructured":"Dispenzieri A, Kastritis E, Wechalekar AD, Sch\u00f6nland SO, Kim K, Sanchorawala V, et al. Primary results from the phase 3 Tourmaline-AL1 trial of ixazomib-dexamethasone versus physician\u2019s choice of therapy in patients (Pts) with relapsed\/refractory primary systemic AL amyloidosis (RRAL). Blood. 2019;134:139.","journal-title":"Blood"},{"issue":"18","key":"626_CR66","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1182\/blood.2019004436","volume":"135","author":"V Sanchorawala","year":"2020","unstructured":"Sanchorawala V, Sarosiek S, Schulman A, Mistark M, Migre ME, Cruz R, et al. Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study. Blood. 2020;135(18):1541\u20137.","journal-title":"Blood"},{"issue":"1","key":"626_CR67","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams D, Gonzalez-Duarte A, O\u2019Riordan WD, Yang CC, Ueda M, Kristen AV, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):11\u201321.","journal-title":"N Engl J Med"},{"issue":"1","key":"626_CR68","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1716793","volume":"379","author":"MD Benson","year":"2018","unstructured":"Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):22\u201331.","journal-title":"N Engl J Med"},{"issue":"24","key":"626_CR69","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1001\/jama.2013.283815","volume":"310","author":"JL Berk","year":"2013","unstructured":"Berk JL, Suhr OB, Obici L, Sekijima Y, Zeldenrust SR, Yamashita T, et al. Repurposing diflunisal for familial amyloid polyneuropathy a randomized clinical trial. Jama-J Am Med Assoc. 2013;310(24):2658\u201367.","journal-title":"Jama-J Am Med Assoc"},{"issue":"8","key":"626_CR70","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","volume":"79","author":"T Coelho","year":"2012","unstructured":"Coelho T, Maia LF, Martins da Silva A, Waddington Cruz M, Plante-Bordeneuve V, Lozeron P, et al. Tafamidis for transthyretin familial amyloid polyneuropathy a randomized, controlled trial. Neurology. 2012;79(8):785\u201392.","journal-title":"Neurology"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-021-00626-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11899-021-00626-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-021-00626-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T12:18:26Z","timestamp":1672402706000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11899-021-00626-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,9]]},"references-count":70,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["626"],"URL":"https:\/\/doi.org\/10.1007\/s11899-021-00626-4","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,9]]},"assertion":[{"value":"21 March 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Michael Rosenzweig:Honoraria: Bristol Myers Squibb, Janssen, Takeda, Akcea, Abbvie, OncopeptidesFaizi Jamal:None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}